Drug Research

Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy

December 11, 2017

SAN DIEGO, Dec. 09, 2017 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the generation of chimeric antigen receptor (CAR)-targeted CD8αβ+ T cells from a clonal engineered master pluripotent cell line (MPCL). The clonal engineered MPCL was created […]

Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

December 11, 2017

CAMBRIDGE, Mass., Dec. 10, 2017 – Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two presentations reinforcing its commitment to identifying predictors of response to tazemetostat beyond EZH2 mutations will be featured at the 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) in Atlanta, […]

Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting

December 11, 2017

ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using the CRISPR technology, and its collaborator, Novartis, presented initial data from their research collaboration on genome-edited human hematopoietic stem cells. These data showed successful ex vivo editing of the erythroid […]

Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting

December 11, 2017

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) — Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel G9a program for sickle cell disease (SCD). The data were reported during an oral presentation at the 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) […]

INTERPHEX JAPAN 2017/in-PHARMA JAPAN 2017 concluded with a huge success.

December 7, 2017

INTERPHEX JAPAN 2017 and in-PHARMA JAPAN 2017 were held at Tokyo Big Sight, Japan during 28 -30 June, 2017. Japan’s largest* B-to-B trade show specialised in Pharmaceutical R&D and Manufacturing concluded with a huge success (*in reference to the exhibitor number with the same concept.) 30th anniversary year of INTERPHEX JAPAN ended a remarkable success: […]

Cancer Research Institute Announces Publication of Comprehensive Immuno-Oncology Landscape Analysis in Annals of Oncology

December 7, 2017

NEW YORK, December 7, 2017—The Cancer Research Institute (CRI) announced today the publication of a report that provides a first-of-its-kind independent analysis of the global immuno-oncology (IO) landscape, from agents in pre-clinical development to regulatory approval. The report quantifies a significant number of IO agents in development and this level of activity will likely result […]

Leveraging Real-World Evidence for Regenerative Medicine and Advanced Therapy Success Beyond the Regulator

December 7, 2017

In the Fall issue of The Evidence Forum, one of the many informative articles covers the promising opportunities of regenerative medicine in reversing or significantly impacting the progression of – and costs associated with – serious illnesses. These treatments have the potential to transform the healthcare landscape, offering transformative, durable, and (in some cases) even […]

Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

December 6, 2017

SHELTON, Conn., Dec. 6, 2017 /PRNewswire/ — NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports that it has begun initial safety and toxicology evaluation of its optimized nanoviricides® drug candidates developed against varicella-zoster virus (VZV), the shingles virus. This study is an important step in the drug development pathway for a treatment for shingles, a […]

Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells

December 6, 2017

SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results of a preclinical study of novel immuno-oncology molecules derived from the company’s variant immunoglobulin (Ig) domain (vIgD) platform. Alpine scientists fused these novel molecules with trastuzumab with the goal of activating T cells […]

Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

December 6, 2017

SHELTON, Conn., Dec. 6, 2017 /PRNewswire/ — NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports that it has begun initial safety and toxicology evaluation of its optimized nanoviricides® drug candidates developed against varicella-zoster virus (VZV), the shingles virus. This study is an important step in the drug development pathway for a treatment for shingles, a […]

STA Pharmaceutical Sees Rapid Growth in MAH Programs in China

December 5, 2017

STA Pharmaceutical (STA) – a China-based global API and Drug Product CDMO – reports that it has seen a rapid uptake in companies with intent to market their products in China using it as a development and manufacturing partner following the CFDA’s announcement of the new Market Authorization Holder (MAH) pilot program last year in […]

Certara Launches Version 17 of its PBPK Simcyp Simulator

December 5, 2017

This year’s Simcyp Simulator enhancements include new oncology and preterm-birth populations, enhanced skin and gut transporter models, and additional regulatory qualification summaries Certara®, the global leader in model-informed drug development and regulatory science, today announced that it has launched version 17 of its Simcyp® Population-based Simulator. “We are proud to introduce several significant advances in […]

Lakewood-Amedex Inc. Advances Bisphosphocin Nu-8 to IND-Enabling Studies to Treat Complicated Urinary Tract Infection

December 4, 2017

SARASOTA, Fla., December 4, 2017 – Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will be advancing a second Bisphosphocin drug candidate, Nu-8, into preclinical IND-enabling studies following pre-IND written communications with the U.S. Food and Drug Administration (FDA). Nu-8 will be developed for the treatment of complicated urinary tract infections […]

Peptides 2018

November 30, 2017

HPAPI 2018

November 30, 2017
FEEDBACK